A Myriad Genetics, Inc. (Nasdaq:MYGN) today release revealed that data providing further clinical validation supporting its newest molecular diagnostic product, PROLARIS, was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
The study at the Scott and White Clinic, Temple, Texas examined a well-described cohort of patients for which 10-year follow-up data were available following prostatectomy surgery. The study demonstrated that the PROLARIS molecular diagnostic test is a significant predictor of prostate cancer recurrence in training.
The abstract of the presentation entitled: “Cell Cycle Genes Predict Recurrence After Radical Prostatectomy” is now available on the American Society of Clinical Oncology’s website.
No User Responded In This Post
Before Leave Your Comments Here Click Below On Our Sponsors...